Oricell brings first pivotal-stage CAR T in liver cancer
· tamra sami
AI Briefing
- • Oricell's CAR T therapy Ori-C101 targets GPC3-positive liver cancer in a confirmatory trial.
- • Ori-C101 is the first CAR T therapy for liver cancer to reach pivotal-stage development.
- • It is the first GPC3-directed immune cell therapy to enter a confirmatory phase II trial.
Source Summary
Oricell Therapeutics Holdings Ltd.’s glypican-3 (GPC3)-targeted autologous CAR T therapy, Ori-C101, is heading into a confirmatory registration phase II trial in patients with GPC3-positive advanced hepatocellular carcinoma, positioning it as the first GPC3-directed immune cell therapy – and the first CAR T therapy for liver cancer – to reach that stage of development.
Advertisement